Transparency Market Research (TMR) has published a new report
titled “Macular degeneration treatment Market - Global Industry Analysis, Size,
Share, Growth, Trends, and Forecast, 2018–2026.” According to the report,
the global macular degeneration treatment
market was
valued at US$ 6.1 Bn in 2017. It is projected to expand at a CAGR of 6.4% from
2018 to 2026. Age-related macular degeneration treatment (AMD) is the leading
cause of irreversible blindness. According to the National Institutes of
Health, in the U.S. from 2000 to 2010, the number of people with AMD increased
by 18%, from 1.75 million to 2.07 million. Moreover, nearly 5.44 million
individuals are expected to develop AMD in the near future in the U.S. AMD is
classified into three stages: early AMD, intermediate AMD, and late AMD. Late
AMD is the advanced stage of AMD, which is characterized by the presence of
late dry AMD (geographic atrophy) or late wet AMD (neovascular or
exudative).
Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60645
The report offers detailed segmentation of the global macular
degeneration treatment market based on disease indication, drug class, and
distribution channel. The market has also been segregated based on region
(North America, Europe, Asia Pacific, Latin America, and Middle East &
Africa). The Anti-VEGF therapies segment is likely to drive the global market.
Key players are tapping opportunities to introduce therapies for geographic
atrophy, which are expected to boost the number of treated geographic atrophy
cases, thereby drive the macular degeneration treatment market. Research and
development of groundbreaking drugs could increase, as several patents stand on
the brink of expiry. Consequently, enrolment in clinical trials is expected to rise
in the near future. Companies are likely to ink licensing agreements and forge
tactical collaborations to strengthen their position in the market. They are
anticipated to back their blockbuster drugs in order to win over their rivalry
with other players. Bayer, Regeneron, Roche/Genentech, and Novartis AG are some
companies that could make their presence known in the market.
Enquiry Before Buying Macular Degeneration Treatment
Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=60645
Technical advancements and
promising pipeline products assure improved growth
Growing prevalence of AMD is expected to boost the global market,
while this could be an obvious growth factor of the market, there are other
factors that are expected to propel the market in the near future. For
instance, increase in healthcare expenditure and patient awareness are expected
to boost the market. Moreover, introduction of advanced medications in AMD is
also projected to propel the market.
Launch of novel products for the treatment of geographic atrophy,
late stage of dry age-related
macular degeneration treatment (dAMD), and wet AMD (wAMD) are key drivers of the
AMD market. Drugs such as Apellis’ APL-2, Ophthotech’s Zimura and Novartis’
longer-acting anti-VEGF, brolucizumab are estimated to fuel the global macular
degeneration treatment market. In particular, the launch of drugs into the AMD
market to treat dAMD is anticipated to be a major factor, as currently, no
prescription medications are available for these patients.
Request For Discount - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=60645
Brands with drug patents accused
of extortionately pricing high demand products
Patent expiry is likely to pose a threat to the expansion of
market players. On the other hand, exorbitant pricing may not be a good
strategy to adopt for players who possess patents for their drugs. For
instance, patent expire of Lucentis during the forecast period. Several
companies are in the race to introduce Lucentis biosimilar for monthly
treatment of neovascular age-related macular degeneration treatment (nAMD),
with plans to bring introduce it into the market during the forecast period,
such as Samsung Bioepis, SB11 and bioeq, FYB201. Moreover, a lack of
prescription drugs in the international AMD market is expected to hamper demand
in the near future.
Specialty clinics segment to
expand at rapid pace
The hospitals segment accounted for a significant share of the
global market, followed by the ophthalmic clinics segment, in 2017. The
ophthalmic clinics segment is anticipated to expand at a high CAGR during the
forecast period. Affordable health care facilities provided in specialty
clinics is a major factor fueling the segment. Ophthalmic clinics is the
second-leading segment, as the primary detection and treatment of AMD are
carried out at hospitals. The ambulatory surgical centers segment accounted for
a relatively minor share of the market. It is expected to expand at a steady
pace during the forecast period.
Buy now Macular Degeneration Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=60645<ype=S
Market in North America to
register exponential growth
In terms of revenue, the macular degeneration treatment market in
North America is projected to expand at a CAGR of 6.9% during the forecast
period. North America dominated the global macular degeneration treatment
market, in terms of revenue, in 2017. It is projected to maintain its dominant
position during the forecast period. High rate of adoption of prescription AMD
drugs in the U.S. and increasing number of approvals for new drugs from the
U.S. FDA are major factors responsible for the high share held by North America
in 2017.
More Trending Reports by
Transparency Market Research:
https://www.prnewswire.com/news-releases/global-optical-lens-edger-market-to-thrive-on-growing-popularity-of-digital-camera-market-projected-to-clock-impressive-6-5-cagr-from-2018--2026--tmr-301283241.html
https://www.prnewswire.com/news-releases/manufacturers-in-injection-pen-market-aimed-at-improving-diabetes-care-to-propel-constant-design-advances-by-2030-global-valuation-to-climb-to-us-6-bn-tmr-301287473.html
https://www.prnewswire.com/news-releases/interest-of-skin-care-experts-for-new-treatment-possibilities-new-drug-formulations-for-large-populations-with-scar-to-underscore-growth-in-scar-treatment-market-valuation-projected-to-climb-us-32-1-bn-by-2027--tmr-301292522.html
About Us
Transparency Market Research (TMR) is a global market intelligence
company providing business information reports and services. The company’s
exclusive blend of quantitative forecasting and trend analysis provides
forward-looking insight for thousands of decision makers. TMR’s experienced
team of analysts, researchers, and consultants use proprietary data sources and
various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest trends and
information. With extensive research and analysis capabilities, Transparency
Market Research employs rigorous primary and secondary research techniques to
develop distinctive data sets and research material for business reports.
Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
